期刊
LEUKEMIA
卷 26, 期 10, 页码 2245-2253出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2012.101
关键词
CRLF2; pediatric BCP-ALL; prognosis
资金
- Fondazione Citta della Speranza (Padova)
- Fondazione Tettamanti (Monza)
- Associazione Italiana Ricerca sul Cancro (AIRC)
- CARIPARO Project of Excellence
- MIUR
- Fondazione Cariplo
- Deutsche Krebshilfe
- Madeleine-Schickedanz-Kinderkrebsstiftung
- Israel Science Foundation Legacy Program
- Children with Leukaemia UK
Pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) has achieved an 80% cure rate as a result of a risk-adapted therapy largely based on minimal residual disease (MRD) monitoring. However, relapse is still the most frequent adverse event, occurring mainly in the patients with intermediate MRD levels (intermediate risk, IR), emphasizing the need for new prognostic markers. We analyzed the prognostic impact of cytokine receptor-like factor 2 (CRLF2) over-expression and P2RY8-CRLF2 fusion in 464 BCP-ALL patients (not affected by Down syndrome and BCR-ABL negative) enrolled in the AIEOP-BFM ALL2000 study in Italy. In 22/464 (4.7%) samples, RQ-PCR showed CRLF2 over-expression (>= 20 times higher than the overall median). P2RY8-CRLF2 fusion was detected in 22/365 (6%) cases, with 10/22 cases also showing CRLF2 over-expression. P2RY8-CRLF2 fusion was the most relevant prognostic factor independent of CRLF2 over-expression with a threefold increase in risk of relapse. Significantly, the cumulative incidence of relapse of the P2RY8-CRLF2+ patients in the IR group was high (61.1% +/- 12.9 vs 17.6% +/- 2.6, P < 0.0001), similar to high-risk patients in AIEOP-BFM ALL2000 study. These results were confirmed in a cohort of patients treated in Germany. In conclusion, P2RY8-CRLF2 identifies a subset of BCP-ALL patients currently stratified as IR that could be considered for treatment intensification.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据